Parameters ACE genotypes T-test
  II ID/DD t P-value
Age (years) 52.9 ± 1.2 53.3 ± 2.5 0.72 0.47
Duration (years) 5.9 ± 3.9 6.4 ± 4.8 0.36 0.71
Fasting blood glucose (mg/dl) 225.8 ± 17.8 240.9 ± 33.2 1.70 0.09
2-h PP blood glucoseĀ  (mg/dl) 301 ± 84.4 315 ± 47.3 0.75 0.45
HDL (mg/dl) 47.5 ± 6.5 43.3 ± 8.8 1.70 0.09
TAG (mg/dl) 171 ± 43.1 195.5 ± 55.4 1.55 0.12
TC (mg/dl) 234.5 ± 42.8 281 ± 45.7 3.42 0.001*
LDL (mg/dl) 195.5 ± 36.2 228.7 ± 49.1 2.40 0.01*
Fasting insulin (μIU/ml) 9.1 ± 4.5 13.1 ± 5.6 2.49 0.01*
HOMA-IR 6.1 ± 3.3 6.5 ± 4.2 0.33 0.73
Urinary Albumin/Creatinine ratio (UACR , mg/g) 37.9 ± 4.6 40.5 ± 5.8 1.57 0.12
Urea (mg %) 47.4 ± 14.8 49.9 ± 17.2 0.50 0.61
Serum creatinine (mg/dl) 0.93 ± 0.45 0.98 ± 0.33 0.44 0.65
estimated GFR (eGFR ,ml/min per 1.73m2 ) 88.26 ± 49.1 81.33 ± 27.9 0.63 0.52
sRAGE, pg/mL 4450 ± 311 4667 ± 367 2.04 0.04*
Pentosidineng/ml 249 ± 37 285 ± 46 2.73 0.008*
AOPP(μmol/l) 178 ± 8.7 189 ± 3.4 6.45 <0.001*
Data presented as means ± SD. P was calculated by T-test. P was considered significant at <0.05.;*Significant HOMA-IR: Homeostatic Model Assessment of Insulin Resistance, sRAGE: soluble receptor for advanced glycation end-products, AOPP:advanced oxidation protein products
Table 4: association between distribution of angiotensin converting enzyme insertion/deletion (ACE I/ D) genotypes and the studied parameters in T2 diabetic patients with and without microalbuminuria